{
  "schema_version": "5.0",
  "artifact_kind": "company_profile",
  "language": "zh-CN",
  "generated_on": "2026-11-09",
  "research_as_of": "2026-11-09",
  "input_context": {
    "name_zh": "百济神州",
    "name_en": "BeiGene",
    "industry_level1": "医药健康",
    "industry_level2": "",
    "official_website": "www.beigene.com",
    "company_type": "品牌方",
    "logo_url": "https://cdn.brandfetch.io/domain/www.beigene.com/w/256/h/256/fallback/lettermark/type/icon?c=1idH6DEOXL4sEn7V6hN"
  },
  "entity": {
    "name_zh": "百济神州",
    "name_en": "BeOne Medicines Ltd.",
    "scope": "原BeiGene集团的延续主体BeOne Medicines Ltd.及其合并子公司；保留输入表头百济神州／BeiGene，正文采用现行英文集团及药品品牌名称。",
    "legal_name_zh": "BeOne Medicines Ltd.（原BeiGene, Ltd.）",
    "corporate_website": "https://beonemedicines.com/",
    "source_ids": [
      "S01",
      "S03"
    ]
  },
  "basic_info": [
    {
      "key": "legal_name",
      "label": "法定主体或所属主体",
      "value": "BeOne Medicines Ltd.（原BeiGene, Ltd.）",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "founded",
      "label": "成立时间",
      "value": "2010",
      "scope": "集团创立；2025年迁册瑞士及英文更名为延续变更",
      "source_ids": [
        "S01"
      ]
    },
    {
      "key": "headquarters",
      "label": "总部",
      "value": "瑞士巴塞尔",
      "scope": "年报列示的主要行政办公地，集团在多国设研发与经营设施",
      "source_ids": [
        "S01",
        "S04"
      ]
    },
    {
      "key": "listing",
      "label": "上市情况",
      "value": "纳斯达克ONC（ADS）；香港联交所06160；上交所科创板688235",
      "source_ids": [
        "S02",
        "S01"
      ]
    },
    {
      "key": "employees",
      "label": "员工人数",
      "value": 12000,
      "unit": "人",
      "as_of": "2026-02-13",
      "scope": "集团全球全职员工，年报表述为接近12,000人",
      "statement_date": "2026-02-26",
      "operator": "~",
      "source_ids": [
        "S01"
      ],
      "display": "约12,000人"
    },
    {
      "key": "revenue",
      "label": "营业收入",
      "value": 5343033000,
      "unit": "美元",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "集团合并总收入，含产品及其他收入，US GAAP，经审计",
      "statement_date": "2026-02-26",
      "source_ids": [
        "S01"
      ],
      "display": "5,343,033,000美元"
    },
    {
      "key": "current_year_revenue",
      "label": "今年营业收入",
      "value": 5108324000,
      "unit": "美元",
      "period": {
        "start": "2026-01-01",
        "end": "2026-09-30",
        "basis": "calendar_year"
      },
      "scope": "集团合并总收入，未经审计",
      "statement_date": "2026-11-05",
      "source_ids": [
        "S02"
      ],
      "display": "5,108,324,000美元"
    },
    {
      "key": "international_revenue",
      "label": "国际业务收入",
      "value": 3663502000,
      "unit": "美元",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "中国以外收入，按年报地域总收入计算",
      "statement_date": "2026-02-26",
      "source_ids": [
        "S01"
      ],
      "display": "3,663,502,000美元"
    },
    {
      "key": "international_revenue_share",
      "label": "国际收入占比",
      "value": 68.57,
      "unit": "%",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "中国以外收入占集团总收入，计算值",
      "statement_date": "2026-02-26",
      "source_ids": [
        "S01"
      ],
      "display": "68.57%"
    },
    {
      "key": "sales_coverage",
      "label": "销售覆盖国家及地区",
      "value": [
        "美国",
        "日本",
        "韩国",
        "巴西",
        "加拿大",
        "澳大利亚"
      ],
      "scope": "按实际商业化、批发供药或分销资料确认的部分境外市场",
      "display_countries": [
        "美国",
        "日本",
        "韩国",
        "巴西",
        "加拿大"
      ],
      "source_ids": [
        "S01",
        "S02",
        "S09",
        "S10",
        "S11"
      ],
      "display": "已核实6个境外市场"
    }
  ],
  "overview": {
    "paragraphs": [
      {
        "text": "百济神州是一家覆盖发现、开发、制造与商业化的全球肿瘤药物企业。集团于2010年创立，2025年迁册瑞士并将英文名称由BeiGene, Ltd.变更为BeOne Medicines Ltd.，主要行政办公地位于巴塞尔。原官网已转向现行全球站点，业务及上市主体属于延续关系。",
        "source_ids": [
          "S01",
          "S03"
        ]
      },
      {
        "text": "公司围绕血液肿瘤和实体瘤建立药物组合，已商业化的核心自研品牌为BRUKINSA、TEVIMBRA和BEQALZI。其研发组织同时推进小分子抑制剂、抗体、抗体药物偶联物和蛋白降解等方向，并借助区域授权及联合开发扩大药物组合。临床阶段候选药物仍处于研发过程。",
        "source_ids": [
          "S01",
          "S02",
          "S03",
          "S07"
        ]
      }
    ]
  },
  "business": {
    "paragraphs": [
      {
        "text": "BRUKINSA以口服BTK抑制剂zanubrutinib为核心，用于相关B细胞恶性肿瘤，形成全球血液肿瘤商业业务的重要基础。BEQALZI的核心成分为BCL2抑制剂sonrotoclax，2026年在美国获得特定复发或难治套细胞淋巴瘤适应证的加速批准，为既往治疗后的患者人群新增药物选择。",
        "source_ids": [
          "S01",
          "S05",
          "S02"
        ]
      },
      {
        "text": "TEVIMBRA是以tislelizumab为核心的抗PD-1免疫治疗抗体，覆盖实体瘤相关治疗场景，单药或联合方案的适应证因市场而异。2026年8月，美国批准其与ZIIHERA及化疗组成特定HER2阳性胃食管腺癌一线治疗方案，扩展其在海外的获批应用范围。",
        "source_ids": [
          "S01",
          "S06"
        ]
      },
      {
        "text": "合作组合中，公司拥有ZIIHERA在部分亚洲市场及澳新地区的开发和商业权益，美国该药由Jazz负责商业化。与Revolution Medicines的新合作涉及四款临床阶段RAS(ON)候选药物的联合开发与部分亚洲区域权益，后者保留日本、韩国及其他未授权区域的权利。",
        "source_ids": [
          "S01",
          "S06",
          "S07"
        ]
      },
      {
        "text": "研发与制造网络支持药物自主推进。公司在中国苏州、广州及美国Hopewell布局生产与研发能力，既生产小分子药物，也建立大分子生物药制造能力；新增Hopewell小分子产能仍属扩建计划。药品医学信息与患者支持围绕已上市药物开展，药物供给由各地商业组织与渠道承接。",
        "source_ids": [
          "S01",
          "S04",
          "S08",
          "S09"
        ]
      }
    ],
    "brands": [
      {
        "name": "BRUKINSA",
        "description": "集团自研口服BTK抑制剂药品品牌，通用名zanubrutinib（泽布替尼），面向血液肿瘤市场。",
        "source_ids": [
          "S01",
          "S03"
        ],
        "website": "https://beonemedicines.com/science/medicines/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "抗肿瘤药物"
          }
        ],
        "products": [
          {
            "category": "口服抗肿瘤靶向药",
            "series": [],
            "representative_products": [
              {
                "name": "zanubrutinib（泽布替尼）",
                "website": null
              }
            ],
            "description": "以zanubrutinib为活性成分，覆盖慢性淋巴细胞白血病、小淋巴细胞淋巴瘤等已获批B细胞肿瘤适应证；不同市场的适应证与片剂、胶囊供应范围不同。",
            "source_ids": [
              "S01",
              "S03",
              "S09",
              "S11"
            ],
            "website": "https://beonemedicines.com/science/medicines/"
          }
        ],
        "services": []
      },
      {
        "name": "TEVIMBRA",
        "description": "集团自研抗PD-1免疫治疗药品品牌，通用名tislelizumab（美国命名tislelizumab-jsgr）。",
        "source_ids": [
          "S01",
          "S03",
          "S06"
        ],
        "website": "https://beonemedicines.com/science/medicines/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "抗肿瘤药物"
          }
        ],
        "products": [
          {
            "category": "抗肿瘤免疫治疗抗体",
            "series": [],
            "representative_products": [
              {
                "name": "tislelizumab／tislelizumab-jsgr",
                "website": null
              }
            ],
            "description": "以tislelizumab为核心的静脉用抗PD-1抗体，包含已获当地批准的单药及联合治疗方案；美国2026年新增与ZIIHERA及化疗联合的特定HER2阳性胃食管腺癌适应证。",
            "source_ids": [
              "S01",
              "S06"
            ],
            "website": "https://beonemedicines.com/science/medicines/"
          }
        ],
        "services": []
      },
      {
        "name": "BEQALZI",
        "description": "集团BCL2抑制剂sonrotoclax的海外药品品牌，美国于2026年授予特定适应证加速批准。",
        "source_ids": [
          "S03",
          "S05",
          "S02"
        ],
        "website": "https://beonemedicines.com/science/medicines/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "抗肿瘤药物"
          }
        ],
        "products": [
          {
            "category": "口服抗肿瘤靶向药",
            "series": [],
            "representative_products": [
              {
                "name": "sonrotoclax",
                "website": null
              }
            ],
            "description": "sonrotoclax在美国加速批准用于既往接受至少两线全身治疗、其中包括BTK抑制剂的成人复发或难治套细胞淋巴瘤。",
            "source_ids": [
              "S05",
              "S03"
            ],
            "website": "https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma"
          }
        ],
        "services": []
      }
    ],
    "services": []
  },
  "global_presence": {
    "paragraphs": [
      {
        "text": "公司已在美国形成核心药品商业收入，年报明确BRUKINSA已在日本、韩国及巴西等市场推出。加拿大官网提供面向药房的批发商订购渠道，加拿大卫生部登记其状态为已上市销售；澳大利亚药品资料列明当地分销公司。欧洲也是集团的重要收入来源。",
        "source_ids": [
          "S01",
          "S02",
          "S09",
          "S10",
          "S11"
        ]
      },
      {
        "text": "经营网络横跨六洲，包括中国研发及生产设施、美国Hopewell生物药制造与临床研发设施、巴塞尔主要行政办公室，以及欧洲、亚洲、拉美、澳洲和南非的区域办公室。集团同时拥有自有设施与实际租用空间，办公室名单与药品可售地区分别披露。",
        "source_ids": [
          "S01",
          "S04"
        ]
      }
    ],
    "market_regions": [
      {
        "region": "亚洲",
        "countries": [
          "日本",
          "韩国"
        ],
        "coverage": "partial",
        "source_ids": [
          "S01"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      },
      {
        "region": "非洲",
        "countries": [
          "-"
        ],
        "coverage": "partial",
        "source_ids": []
      },
      {
        "region": "北美洲",
        "countries": [
          "美国",
          "加拿大"
        ],
        "coverage": "partial",
        "source_ids": [
          "S02",
          "S09",
          "S10"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "巴西"
        ],
        "coverage": "partial",
        "source_ids": [
          "S01"
        ]
      },
      {
        "region": "大洋洲",
        "countries": [
          "澳大利亚"
        ],
        "coverage": "partial",
        "source_ids": [
          "S11"
        ]
      }
    ],
    "operating_regions": [
      {
        "region": "亚洲",
        "countries": [
          "中国",
          "马来西亚",
          "韩国",
          "新加坡",
          "泰国",
          "日本",
          "阿联酋",
          "以色列",
          "沙特阿拉伯"
        ],
        "coverage": "partial",
        "source_ids": [
          "S04",
          "S01"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "瑞士",
          "法国",
          "德国",
          "意大利",
          "荷兰",
          "西班牙",
          "瑞典",
          "英国"
        ],
        "coverage": "partial",
        "source_ids": [
          "S04",
          "S01"
        ]
      },
      {
        "region": "非洲",
        "countries": [
          "南非"
        ],
        "coverage": "partial",
        "source_ids": [
          "S04",
          "S01"
        ]
      },
      {
        "region": "北美洲",
        "countries": [
          "美国",
          "加拿大",
          "墨西哥"
        ],
        "coverage": "partial",
        "source_ids": [
          "S04",
          "S01"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "阿根廷",
          "智利",
          "巴西"
        ],
        "coverage": "partial",
        "source_ids": [
          "S04",
          "S01"
        ]
      },
      {
        "region": "大洋洲",
        "countries": [
          "澳大利亚"
        ],
        "coverage": "partial",
        "source_ids": [
          "S04"
        ]
      }
    ]
  },
  "developments": {
    "window": {
      "start": "2025-11-09",
      "end": "2026-11-09",
      "max_items": 5
    },
    "items": [
      {
        "id": "D01",
        "title": "披露BRUKINSA一线套细胞淋巴瘤方案获优先审评",
        "importance": "major",
        "display_date": "2026-11-05",
        "summary": "公司在三季度业务更新中披露，基于MANGROVE研究的BRUKINSA联合方案申报获美国FDA优先审评，并已完成欧盟及中国的相应监管提交；日本申报列入2026年第四季度计划。",
        "status": "announced",
        "source_ids": [
          "S02"
        ]
      },
      {
        "id": "D02",
        "title": "公布美国药品可及性及本土制造协议",
        "importance": "major",
        "display_date": "2026-08-31",
        "summary": "BeOne公布与美国政府达成自愿协议，涉及Medicaid相关定价模式及本土制造安排，并介绍Hopewell追加3亿美元小分子制造扩建计划，预计新增约120个全职岗位。",
        "status": "announced",
        "source_ids": [
          "S08"
        ]
      },
      {
        "id": "D03",
        "title": "TEVIMBRA联合方案获美国FDA新适应证批准",
        "importance": "major",
        "display_date": "2026-08-25",
        "summary": "FDA批准TEVIMBRA与ZIIHERA及含氟嘧啶、铂类化疗联合，用于特定HER2阳性的不可切除局部晚期或转移性胃、胃食管结合部或食管腺癌成人患者的一线治疗。",
        "status": "completed",
        "source_ids": [
          "S06"
        ]
      },
      {
        "id": "D04",
        "title": "与Revolution Medicines达成临床及区域权益合作",
        "importance": "major",
        "display_date": "2026-08-10",
        "summary": "双方宣布开展四款临床阶段RAS(ON)抑制剂与BeOne肿瘤资产的联合开发，并授予BeOne部分亚洲市场的开发及商业化权益。日本、韩国及其余未授权地区的权利由Revolution Medicines保留。",
        "status": "announced",
        "source_ids": [
          "S07"
        ]
      },
      {
        "id": "D05",
        "title": "BEQALZI获美国FDA加速批准",
        "importance": "major",
        "display_date": "2026-05-13",
        "summary": "FDA授予BCL2抑制剂BEQALZI（sonrotoclax）加速批准，用于既往接受至少两线全身治疗、其中包括BTK抑制剂的成人复发或难治套细胞淋巴瘤患者。",
        "status": "completed",
        "source_ids": [
          "S05"
        ]
      }
    ]
  },
  "sources": [
    {
      "id": "S01",
      "title": "BeOne Medicines 2025年度Form 10-K年报",
      "url": "https://ir.beonemedicines.com/media/document/fbc4ae55-8803-4bdf-8fd1-2b37e1b8efab/assets/BeOne_Medicines_Ltd._-_2025_Annual_Report.pdf?disposition=inline",
      "type": "official_report",
      "accessed_on": "2026-11-09",
      "published_at": "2026-02-26"
    },
    {
      "id": "S02",
      "title": "BeOne Medicines 2026年第三季度业绩与业务更新",
      "url": "https://ir.beonemedicines.com/media/document/c804b640-47c3-41c5-8a00-26f90d06eff0/assets/BeOne_Q3_2026_Earnings_FINAL.pdf?disposition=inline",
      "type": "official_report",
      "accessed_on": "2026-11-09",
      "published_at": "2026-11-05"
    },
    {
      "id": "S03",
      "title": "BeOne Medicines全球药品目录",
      "url": "https://beonemedicines.com/science/medicines/",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S04",
      "title": "BeOne Medicines全球办公室与设施",
      "url": "https://beonemedicines.com/about/offices/",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S05",
      "title": "FDA授予sonrotoclax用于复发或难治套细胞淋巴瘤的加速批准",
      "url": "https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-sonrotoclax-relapsed-or-refractory-mantle-cell-lymphoma",
      "type": "regulatory",
      "accessed_on": "2026-11-09",
      "published_at": "2026-05-13"
    },
    {
      "id": "S06",
      "title": "FDA批准zanidatamab与tislelizumab的HER2阳性胃食管腺癌方案",
      "url": "https://www.fda.gov/drugs/cancer-approvals/fda-approves-zanidatamab-hrii-and-tislelizumab-jsgr-her2-positive-gastric-gastroesophageal-junction",
      "type": "regulatory",
      "accessed_on": "2026-11-09",
      "published_at": "2026-08-25"
    },
    {
      "id": "S07",
      "title": "Revolution Medicines与BeOne临床及区域商业化合作公告",
      "url": "https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-and-beone-medicines-announce-clinical",
      "type": "official_news",
      "accessed_on": "2026-11-09",
      "published_at": "2026-08-10"
    },
    {
      "id": "S08",
      "title": "BeOne公布与美国政府达成药品可及性及本土制造协议",
      "url": "https://ir.beonemedicines.com/news/beone-medicines-announces-voluntary-agreement-with-us-government-to-expand-access-to-innovative-cancer-medicines/52be74b5-b198-42d1-8bd0-225480e3986a",
      "type": "official_news",
      "accessed_on": "2026-11-09",
      "published_at": "2026-08-31"
    },
    {
      "id": "S09",
      "title": "BeOne加拿大药品及订购渠道",
      "url": "https://beonemedicines.ca/en/science/our-medicines/",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S10",
      "title": "加拿大卫生部药品数据库：BRUKINSA",
      "url": "https://health-products.canada.ca/dpd-bdpp/info?code=104313&lang=eng",
      "type": "regulatory",
      "accessed_on": "2026-11-09",
      "published_at": null
    },
    {
      "id": "S11",
      "title": "BRUKINSA澳大利亚产品资料与分销信息",
      "url": "https://www.safetyandquality.gov.au/medicine-finder/brukinsa",
      "type": "official",
      "accessed_on": "2026-11-09",
      "published_at": null
    }
  ],
  "report_template": "core-v4"
}
